Substance Use Disorders in HIV People of Cameroon

NCT02356185 | Unknown

• 1 other identifier: ASSIST-HIV
• Study Type: observational
• Target: 1,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Background: Data are scarce concerning injecting drug use (IDU) and alcohol consumption among HIV-infected people on highly active antiretroviral treatment (HAART) in Cameroon. The aim of this study is to determine the prevalence of alcohol consumption and IDU among HIV-infected people on HAART; to determine sociodemographic factors associated with alcohol abuse and IDU among people on HAART; and to determine impact of alcohol consumption and IDU on adherence to HAART. Methods/Design: The investigators will conduct a cross sectional study at the Yaoundé Central Hospital in Cameroon, from February to August 2015. Using a self-report questionnaire, the investigators will include at least 1,000 HIV-infected adults (18 years or more) on HAART for at least one month coming for HIV care. The investigators will exclude pregnant women. Data collection will include sociodemographic and economic profile, alcohol consumption using Alcohol Use Disorders Identification Test, injecting drug use, adherence to HAART using visual analog scale and self-rate report. The investigators will perform sub-analysis for sex group and area of habitation. A p value \< 0.05 will be considered statistically significant. Discussion: There is a critical need of accurate estimates of the amplitude and the distribution of IDU and alcohol consumption among HIV-infected adults, in order to inform health policies maker for curbing burden of both injecting drug use and alcohol consumption among people living with HIV.

Conditions

HIV

Keywords

Alcohol Drinking; Injecting drug; Antiretroviral therapy; sub-Saharan Africa

Outcome Measures

Primary Outcomes (1)

• Adherence to antiretroviral therapy

  The investigators will measure adherence to antiretroviral therapy using a linear visual analogue scale on the past month as primary method of measure

  All days up to 180 days

Secondary Outcomes (1)

• Self-rate of adherence to antiretroviral therapy

  All days up to 180 days

Other Outcomes (2)

• Alcohol consumption

  All days up to 180 days

• Injecting drug use

  All days up to 180 days

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

HIV infected people

You may qualify if:

• aged 18 years or older
• being for at least one month on highly active antiretroviral therapy

You may not qualify if:

• pregnant women

Sponsors & Collaborators

• Goulfey Health District Unit: lead
• Yaounde Central Hospital: collaborator
• Edea Regional Hospital: collaborator
• University of Yaounde 1: collaborator
• NYU Langone Health: collaborator

Related Publications (22)

• Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, Fox MP, Wood R, Prozesky H, Giddy J, Garone DB, Cornell M, Egger M, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4):e1001418. doi: 10.1371/journal.pmed.1001418. Epub 2013 Apr 9.

  PMID: 23585736 BACKGROUND

• Wood E, Braitstein P, Montaner JS, Schechter MT, Tyndall MW, O'Shaughnessy MV, Hogg RS. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet. 2000 Jun 17;355(9221):2095-100. doi: 10.1016/S0140-6736(00)02375-8.

  PMID: 10902622 BACKGROUND

• Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010 Jun 12;375(9731):2092-8. doi: 10.1016/S0140-6736(10)60705-2. Epub 2010 May 26.

  PMID: 20537376 BACKGROUND

• Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009 Jan 3;373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9. Epub 2008 Nov 27.

  PMID: 19038438 BACKGROUND

• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

  PMID: 21767103 BACKGROUND

• Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, Sabin K, Suthar AB, Mesquita F, Lo YR, Williams B. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e142-9. doi: 10.1097/QAI.0b013e31829b535b.

  PMID: 23714739 BACKGROUND

• Rehm J, Parry CD. Alcohol consumption and infectious diseases in South Africa. Lancet. 2009 Dec 19;374(9707):2053. doi: 10.1016/S0140-6736(09)62150-4. No abstract available.

  PMID: 20109832 BACKGROUND

• Samet JH, Walley AY, Bridden C. Illicit drugs, alcohol, and addiction in human immunodeficiency virus. Panminerva Med. 2007 Jun;49(2):67-77.

  PMID: 17625483 BACKGROUND

• Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res. 2003 May;27(5):862-7. doi: 10.1097/01.ALC.0000065438.80967.56.

  PMID: 12766632 BACKGROUND

• Marcellin F, Boyer S, Protopopescu C, Dia A, Ongolo-Zogo P, Koulla-Shiro S, Abega SC, Abe C, Moatti JP, Spire B, Carrieri MP; EVAL Study Group. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). Trop Med Int Health. 2008 Dec;13(12):1470-8. doi: 10.1111/j.1365-3156.2008.02170.x. Epub 2008 Nov 5.

  PMID: 19000156 BACKGROUND

• L'akoa RM, Noubiap JJ, Fang Y, Ntone FE, Kuaban C. Prevalence and correlates of depressive symptoms in HIV-positive patients: a cross-sectional study among newly diagnosed patients in Yaounde, Cameroon. BMC Psychiatry. 2013 Sep 22;13:228. doi: 10.1186/1471-244X-13-228.

  PMID: 24053612 BACKGROUND

• Pefura-Yone EW, Soh E, Kengne AP, Balkissou AD, Kuaban C. Non-adherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria. J Infect Public Health. 2013 Aug;6(4):307-15. doi: 10.1016/j.jiph.2013.02.003. Epub 2013 Apr 22.

  PMID: 23806707 BACKGROUND

• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010 Dec 1;112(3):178-93. doi: 10.1016/j.drugalcdep.2010.06.014. Epub 2010 Aug 11.

  PMID: 20705402 BACKGROUND

• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202. doi: 10.1097/QAI.0b013e3181b18b6e.

  PMID: 19668086 BACKGROUND

• Neuman MG, Schneider M, Nanau RM, Parry C. Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat. 2012;2012:751827. doi: 10.1155/2012/751827. Epub 2012 Mar 11.

  PMID: 22496971 BACKGROUND

• Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001 Feb;16(2):83-8. doi: 10.1111/j.1525-1497.2001.00122.x.

  PMID: 11251758 BACKGROUND

• Tran BX, Nguyen LT, Do CD, Nguyen QL, Maher RM. Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health. 2014 Jan 10;14:27. doi: 10.1186/1471-2458-14-27.

  PMID: 24411007 BACKGROUND

• Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004 Apr;28(4):572-7. doi: 10.1097/01.alc.0000122103.74491.78.

  PMID: 15100608 BACKGROUND

• Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, Kumar A. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1363-75. doi: 10.1517/17425255.2012.714366. Epub 2012 Aug 8.

  PMID: 22871069 BACKGROUND

• von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007 Nov;85(11):867-72. doi: 10.2471/blt.07.045120.

  PMID: 18038077 BACKGROUND

• Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med. 2000 Jul 10;160(13):1977-89. doi: 10.1001/archinte.160.13.1977.

  PMID: 10888972 BACKGROUND

• Cheng DM, Libman H, Bridden C, Saitz R, Samet JH. Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol. 2009 Feb;43(1):65-71. doi: 10.1016/j.alcohol.2008.09.004.

  PMID: 19185212 BACKGROUND

Related Links

• The World Bank. Cameroon data: The World Bank
• WHO, UNICEF, UNAIDS. Global update on HIV treatment 2013: Results, impact and opportunities 2013
• National Institute of Alcohol Abuse and Alcoholism. NIAAA council approves definition of binge drinking: National Institute of Alcohol Abuse and Alcoholism; 2004
• Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization; 2001

MeSH Terms

Conditions

Alcohol Drinking

Condition Hierarchy (Ancestors)

Drinking Behavior; Behavior

Study Officials

• Jean Joel R Bigna, MD

  Goulfey Health District Unit

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jean Joel R Bigna, MD

CONTACT

+237697224938; bignarimjj@yahoo.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head Officer

Study Record Dates

• First Submitted: December 24, 2014
• First Posted: February 5, 2015
• Study Start: September 1, 2015
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: February 18, 2015

Record last verified: 2015-02